Relative impact of HLA- matching and non-HLA donor characteristics on outcome of allogeneic stem cell transplantation for AML and MDS

Hematopoietic allogeneic stem cell transplantation (HSCT) is an accepted and potentially curative treatment for a variety of hematological diseases, immunodeficiencies and metabolic disorders1, with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) to date representing more than half of the indications in adult patients2. An HLA-matched related donor (MRD) is available for about 25% of patients, while the probability of finding a fully HLA-matched unrelated donor (MUD) varies on average between 60 and 90%3,4.

Source: Biology of Blood and Marrow Transplantation - July 2, 2018 Category: Hematology Authors: Francis Ayuk, Dietrich W. Beelen, Martin Bornh äuser, Matthias Stelljes, Tatjana Zabelina, Jürgen Finke, Guido Kobbe, Daniel Wolff, Eva-Maria Wagner, Maximilian Christopeit, Christoph Schmid, Hellmut Ottinger, Christoph Groth, Christoph Faul, Hartmut Be Source Type: research